Pharmaceuticals Biotechnology and Life Sciences
featured
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
» Read More
More
-
Biotechnology company Novacea and drug developer Schering-Plough said they signed a licensing agreement for prostate cancer treatment candidate Asentar.
-
Merger news and product recalls were some of the catalysts behind the most actively traded stocks on Tuesday.
-
Cramer's been bullish on this stock, but the threat of competition has him wondering if it's worth holding on to. The company's chief executive puts his fears to rest.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
If you happened to be watching CNBC's "Closing Bell" yesterday afternoon, you may have seen what we call a "promo" (short for a promotion of an upcoming story or guest) for a "First on CNBC" interview with GlaxoSmithKline CEO Jean-Pierre (JP) Garnier on today's "Closing Bell" at 3:15 ET.Since the Avandia news broke on Monday, I'd been trying to get an interview with him. He talked to The Wall Street Journal mid-week, but had yet to do a TV interview. Then, yesterday afternoon I got a call from his British PR person telling me that Garnier would like to come on CNBC on Friday. She said he was flying to the States from Europe last night and that we could do a live, one-on-one interview with him at or near the company's U.S. headquarters in Pennsylvania.
-
Earnings updates and contract wins were some of the catalysts behind the most actively traded stocks on Thursday.
-
Asset sales and earnings reports catalyzed the most actively traded stocks on Tuesday.
-
Shares of drug developers Wyeth and Elan jumped Monday after the companies said they plan on asking for approval to move their Alzheimer's treatment candidate bapineuzumab into late-stage studies.
-
M&A news and drug trial updates provided some of the catalysts behind the most actively traded stocks on Monday.
-
Over the past couple of days, a couple of analyst reports have come into my inbox regarding the results of the so-called "CRYSTAL" study of ImClone's Erbitux on metastatic colorectal cancer. ImClone shares Erbitux with Bristol-Myers Squibb. The drug is approved for colon and head and neck cancers, but they're testing it on other tumor types. CRYSTAL is an acronym, but you won't believe how they stretched to create it: Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer. Which came first? The acronym or the study description? Anyway, I digress. Crazy clinical trial acronyms are for another day, another blog entry.
-
Another setback for Amgen anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6% on Tuesday -- to a 2-1/2-year low -- as more analysts cut their ratings on the beaten-down stock.
-
M&A news and quarterly updates provided some of the catalysts behind the most actively traded stocks on Monday.
-
A new study says if a drug is quickly developed that delays the onset of Alzheimer's Disease it would save the U.S. economy trillions of dollars.
-
When it comes to the medical space, proprietary products are where you want to be, Cramer says. Kinetic Concepts' strength in this area make it a good pick for Speculation Friday here on Mad Money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Regulation approval in China recently hurt this company, but Cramer says there's reason to believe the business is on the MEND.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
The slump in retail is actually a good thing for investors, Cramer says. Plus, a sleeper stock worth watching and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Several investment banks slashed their ratings on Amgen shares following the disclosure that a U.S. advisory panel called for marketing restrictions on popular anemia drugs sold by Amgen and Johnson & Johnson.
-
M&A news and analyst actions were some of the catalysts behind the most actively traded stocks on Friday.
-
The founder and former CEO of ImClone Systems, Sam Waksal, who is now sitting in prison for his role in the trading scandal that ensnared Martha Stewart, had a reputation for rubbing elbows with the New York glitterati and the Hollywood set. Well, it looks like ImClone is reliving its past.
-
Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.
-
Analyst actions and earnings updates were some of the catalysts behind the most actively traded stocks on Thursday.